Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 7,855 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 7,855 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $30.79, for a total transaction of $241,855.45. Following the transaction, the chief executive officer now directly owns 597,562 shares in the company, valued at approximately $18,398,933.98. This represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Andrew Cheng also recently made the following trade(s):

• On Monday, December 2nd, Andrew Cheng sold 25,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.09, for a total transaction of $802,250.00.
• On Friday, November 1st, Andrew Cheng sold 108,366 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.73, for a total value of $3,438,453.18.
• On Friday, October 18th, Andrew Cheng sold 63,539 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.53, for a total value of $2,003,384.67.
• On Wednesday, October 16th, Andrew Cheng sold 24,992 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.14, for a total value of $778,250.88.

Akero Therapeutics Stock Down 4.3 %

Shares of NASDAQ:AKRO opened at $29.03 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a 52-week low of $15.32 and a 52-week high of $37.00. The company has a market capitalization of $2.03 billion, a PE ratio of -7.74 and a beta of -0.23. The company has a fifty day moving average of $30.79 and a 200-day moving average of $27.01.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). On average, equities analysts predict that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analyst Ratings Changes

AKRO has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a research note on Monday, November 18th. Citigroup began coverage on Akero Therapeutics in a research note on Monday, November 18th. They set a “buy” rating and a $65.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Akero Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.83.

Institutional Investors Weigh In On Akero Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its holdings in Akero Therapeutics by 54.4% during the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after buying an additional 2,782,029 shares during the period. Janus Henderson Group PLC increased its position in Akero Therapeutics by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock valued at $203,053,000 after purchasing an additional 201,225 shares during the period. RTW Investments LP lifted its position in shares of Akero Therapeutics by 9.0% in the 3rd quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock worth $169,829,000 after purchasing an additional 487,450 shares during the period. Perceptive Advisors LLC increased its position in shares of Akero Therapeutics by 8.1% during the second quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock worth $35,188,000 after buying an additional 112,426 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in Akero Therapeutics during the third quarter worth $37,392,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.